Does ultrasound-guidance improve the outcome of botulinum toxin injections in cervical dystonia?


Journal

Revue neurologique
ISSN: 0035-3787
Titre abrégé: Rev Neurol (Paris)
Pays: France
ID NLM: 2984779R

Informations de publication

Date de publication:
Jun 2022
Historique:
received: 24 06 2021
revised: 29 10 2021
accepted: 02 11 2021
pubmed: 18 12 2021
medline: 16 6 2022
entrez: 17 12 2021
Statut: ppublish

Résumé

Ultrasound-guided injections of botulinum neurotoxin in cervical dystonia have a number of theoretical advantages. However, their action has never been compared to that of non-guided injections. The objectives of the study were to compare the outcome of botulinum neurotoxin type A treatment in patients with idiopathic, focal cervical dystonia, according to two methods: inspection and palpation of anatomical landmarks (non-guided group) or ultrasound guidance (ultrasound-guided group). We included consecutive patients in this single-center, prospective, real-life, non-randomized study. The outcomes were evaluated one month after the injections: Cervical Dystonia Impact Profile 58 (main outcome), Toronto Western Spasmodic Torticollis Rating Scale-2 (pain and disability subscores), Toronto Western Spasmodic Torticollis Rating Scale-PSYCH, patient-rated Clinical Global Impression - Improvement and adverse events. We used propensity score methods for statistical analysis; ten predefined confounding factors were used to build the propensity score. Sixty-three patients were included in the non-guided group, and 60 other patients in the ultrasound-guided group. We found no difference in main and secondary outcomes between the two study groups. This is the first direct comparison between ultrasound-guided and non-guided botulinum neurotoxin type A injections in patients with cervical dystonia. We hypothesize that ultrasound guidance made it possible to obtain the same results in the most severe (or the most demanding) patients as in the best responders. Further studies are still needed to assess the impact of botulinum neurotoxin injections into deep cervical muscles.

Identifiants

pubmed: 34916042
pii: S0035-3787(21)00777-3
doi: 10.1016/j.neurol.2021.11.005
pii:
doi:

Substances chimiques

Neuromuscular Agents 0
Botulinum Toxins, Type A EC 3.4.24.69

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

591-602

Informations de copyright

Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Auteurs

A Kreisler (A)

Movement disorders department, CHU Lille, 59000 Lille, France. Electronic address: alexandre.kreisler@chru-lille.fr.

S Djelad (S)

Movement disorders department, CHU Lille, 59000 Lille, France. Electronic address: Soufiane.djelad@chru-lille.fr.

C Simonin (C)

Movement disorders department, CHU Lille, 59000 Lille, France; University Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, 59000 Lille, France. Electronic address: clemence.simonin@chru-lille.fr.

G Baille (G)

Movement disorders department, CHU Lille, 59000 Lille, France; Hôpital Delafontaine, Neurology Department, 93200 St Denis, France. Electronic address: guillaume.baille@ch-stdenis.fr.

E Mutez (E)

Movement disorders department, CHU Lille, 59000 Lille, France; University Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, 59000 Lille, France. Electronic address: eugenie.mutez@chru-lille.fr.

A Degardin (A)

Movement disorders department, CHU Lille, 59000 Lille, France. Electronic address: adriandegardin@msn.com.

L Defebvre (L)

Movement disorders department, CHU Lille, 59000 Lille, France. Electronic address: luc.defebvre@chru-lille.fr.

J Labreuche (J)

University Lille, CHU Lille, U2694 METRICS, 59000 Lille, France. Electronic address: julien.labreuche.chru@gmail.com.

E Cailliau (E)

University Lille, CHU Lille, U2694 METRICS, 59000 Lille, France. Electronic address: emeline.cailliau.chu@gmail.com.

A Duhamel (A)

University Lille, CHU Lille, U2694 METRICS, 59000 Lille, France. Electronic address: alain.duhamel59@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH